Everhart Financial Group Inc. Sells 1,450 Shares of Danaher Co. (NYSE:DHR)

Everhart Financial Group Inc. lessened its holdings in Danaher Co. (NYSE:DHR - Free Report) by 39.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,205 shares of the conglomerate's stock after selling 1,450 shares during the period. Everhart Financial Group Inc.'s holdings in Danaher were worth $506,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC grew its position in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate's stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate's stock valued at $1,417,342,000 after buying an additional 148,251 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of Danaher by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate's stock valued at $1,265,725,000 after buying an additional 116,299 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate's stock valued at $996,141,000 after buying an additional 535,254 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. lifted its stake in shares of Danaher by 0.6% during the 4th quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate's stock valued at $382,936,000 after buying an additional 9,942 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent research reports. KeyCorp upped their price target on shares of Danaher from $290.00 to $310.00 and gave the company an "overweight" rating in a research note on Wednesday, October 23rd. Barclays lowered their target price on shares of Danaher from $275.00 to $240.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 30th. TD Cowen increased their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. lowered their target price on shares of Danaher from $310.00 to $300.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 28th. Finally, Jefferies Financial Group lowered their target price on shares of Danaher from $285.00 to $260.00 and set a "buy" rating on the stock in a research note on Wednesday, January 29th. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $278.00.

Danaher Trading Down 0.3 %

Shares of DHR stock traded down $0.57 on Wednesday, hitting $203.96. 2,542,687 shares of the company's stock traded hands, compared to its average volume of 4,452,045. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. Danaher Co. has a one year low of $196.80 and a one year high of $281.70. The company's fifty day simple moving average is $228.34 and its 200 day simple moving average is $248.10. The stock has a market capitalization of $147.32 billion, a price-to-earnings ratio of 38.63, a P/E/G ratio of 2.63 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the company posted $2.09 EPS. Equities analysts forecast that Danaher Co. will post 7.67 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date of this dividend was Friday, December 27th. Danaher's dividend payout ratio (DPR) is presently 20.45%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company's stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.90% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.